EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Risk-Based Clinical Data Management

Patrick Nadolny, Catherine Celingant, Leonie Christianson, Pameljit Kalra, Stacey King, Nicole Pollard, Jeffrey Rieske, Jonathan Rowe, Nicolette Okewole, Demi You, Debojyoti Das, Eugene Hayden und 3 weitere

Journal of the Society for Clinical Data Management · 05.10.2026 · 0 (4)

DOI: 10.47912/jscdm.524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Society for Clinical Data Management, online erschienen am 05.10.2026. Verfasst von Patrick Nadolny und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This chapter aims to define principles and best practices for applying risk-based approaches within Clinical Data Management (CDM). These principles are grounded in evolving regulatory expectations. Starting over a decade ago, regulators have issued guidance documents advocating for the adoption of risk-based and fit for purpose approaches. The good clinical practice (GCP) guideline from the International Council for Harmonisation (ICH), commonly referred to as ICH E61, was updated in 2016 and 2025 to reinforce this direction. Additionally, the ICH guideline on General Considerations for Clinical Studies (ICH E8)2 emphasized quality by design (QbD), which is grounded in two foundational risk-based principles: Prospectively identifying factors critical to quality and applying risk-based approaches to study design, conduct, monitoring, and reporting. This includes the use of risk-based approaches to quality management throughout the clinical study lifecycle to support the reliability of study results and the protection of participants. Having already implemented risk-based approaches in the site monitoring and system validation spaces for many years, our traditionally risk-averse industry has become more familiar with strategies that align efforts with the risks to study participants’ rights, safety, and well-being and to data quality. As of 2021, 88% of clinical studies had implemented at least one component of risk-based quality management (RBQM) compared to 53% in 20193. Considering the regulatory evolution and the need to accelerate the development of medicines, it is imperative for organizations managing clinical data and related systems to adopt QbD, RBQM, and fit for purpose principles, focusing on what matters most to participants’ protection and to the reliability of study results.

Zitieren

APA

Nadolny, P., Celingant, C., Christianson, L., Kalra, P., King, S., Pollard, N., Rieske, J., Rowe, J., Okewole, N., You, D., Das, D., Hayden, E., Klein, K., Cesario, L., & Vazquez, M. (2026). Risk-Based Clinical Data Management. Journal of the Society for Clinical Data Management, 0(4). https://doi.org/10.47912/jscdm.524

Vancouver

Nadolny P, Celingant C, Christianson L, Kalra P, King S, Pollard N, et al. Risk-Based Clinical Data Management. Journal of the Society for Clinical Data Management. 2026;0(4). doi:10.47912/jscdm.524

BibTeX
@article{Nadolny2026,
  author = {Nadolny, Patrick and Celingant, Catherine and Christianson, Leonie and Kalra, Pameljit and King, Stacey and Pollard, Nicole and Rieske, Jeffrey and Rowe, Jonathan and Okewole, Nicolette and You, Demi and Das, Debojyoti and Hayden, Eugene and Klein, Karen and Cesario, Lynne and Vazquez, Manny},
  title = {Risk-Based Clinical Data Management},
  journal = {Journal of the Society for Clinical Data Management},
  year = {2026},
  volume = {0},
  number = {4},
  doi = {10.47912/jscdm.524}
}
Kostenlos starten →